Idiopathic Pulmonary fibrosis market size
Sep 26, 2022
PDE4-B Inhibitors: A Promising Target for Idiopathic Pulmonary Fibrosis Treatment
Idiopathic pulmonary fibrosis (IPF) is a rare, sporadic, and fatal interstitial lung disease. As the morbidity and mortality rates associated with IPF remain high, prompt idiopathic pulmonary fibrosis treatment is critical to safeguard individuals’ lung function, reduce the risk of acute exacerbations, and improve ...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
